Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine

References

• National Cancer Institute [homepage on the Internet]Bethesda. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer Available from: http://seer.cancer.gov/statfacts/html/kidrp.html
   Google Scholar
• DoehnCKauschIMelzSBehmAJochamDCytokine and vaccine therapy of kidney cancerExpert Rev Anticancer Ther2004461097111115606336
   PubMedGoogle Scholar
• MotzerRJBukowskiRMTargeted therapy for metastatic renal cell carcinomaJ Clin Oncol200624355601560817158546
   PubMed Web of Science ®Google Scholar
• PartonMGoreMEisenTRole of cytokine therapy in 2006 and beyond for metastatic renal cell cancerJ Clin Oncol200624355584559217158544
   PubMed Web of Science ®Google Scholar
• SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer Available from: www.seer.cancer.govAccessed November 8, 2015
   Google Scholar
• PizzocaroGPivaLColavitaMInterferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized studyJ Clin Oncol200119242543111208835
   PubMed Web of Science ®Google Scholar
• ClarkJIAtkinsMBUrbaWJAdjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trialJ Clin Oncol200321163133314012810695
   PubMed Web of Science ®Google Scholar
• AtzpodienJReitzMMetastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2Cancer Biother Radiopharm200520441041616114989
   PubMed Web of Science ®Google Scholar
• JochamDRichterAHoffmannLAdjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trialLancet2004363940959459914987883
   PubMed Web of Science ®Google Scholar
• MayMBrookman-MaySHoschkeBTen-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant settingCancer Immunol Immunother201059568769519876628
   PubMed Web of Science ®Google Scholar
• Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003814.pdfAccessed November 8, 2015
   Google Scholar
• Guideline on the evaluation of anticancer medicinal products in man: 13th Dec. 2012 EMA/CHMP/205/95/Rev.4 Oncology Working Party Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdfAccessed November 8, 2015
   Google Scholar
• GouttefangeasCStenzlAStevanovićSRammenseeHGImmunotherapy of renal cell carcinomaCancer Immunol Immunother200756111712816676181
   PubMed Web of Science ®Google Scholar
• DoehnCJochamDVaccination immunotherapy – an updateScand J Surg200493216316915285570
   PubMedGoogle Scholar
• LamJSPantuckAJBelldegrunASFiglinRAG250: a carbonic anhydrase IX monoclonal antibodyCurr Oncol Rep2005710911515717944
   PubMedGoogle Scholar
• SaidJBiomarker discovery in urogenital cancerBiomarkers200510Suppl 1S83S8616298916
   PubMed Web of Science ®Google Scholar
• BuiMHSeligsonDHanKRCarbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyClin Cancer Res2003980281112576453
   PubMed Web of Science ®Google Scholar
• IakovlevVVPintilieMMorrisonAFylesAWHillRPHedleyDWEffect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IXLab Invest2007871206121717906661
   PubMed Web of Science ®Google Scholar
• JonesTDEbleJNWangMMaclennanGTJainSChengLClonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformationCancer20051041195120316047350
   PubMed Web of Science ®Google Scholar
• LiGPassebosc-FaureKLambertCFlow cytometric analysis of antigen expression in malignant and normal renal cellsAnticancer Res2000202773277810953356
   PubMed Web of Science ®Google Scholar
• KrishnamurthySBischoffFAnn MayerJDiscordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancerCancer Med20132222623323634290
   PubMed Web of Science ®Google Scholar
• LeeJTHerlynMOld disease, new culprit: tumor stem cells in cancerJ Cell Physiol2007213360360917786956
   PubMed Web of Science ®Google Scholar
• WanTZhouXChenGNovel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvantBlood200410351747175414592822
   PubMed Web of Science ®Google Scholar
• MurshidAGongJCalderwoodSKHeat-shock proteins in cancer vaccines: agents of antigen cross-presentationExpert Rev Vaccines2008771019103018767951
   PubMed Web of Science ®Google Scholar
• CalderwoodSKTumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapyDiscov Med2013158218819423545047
   PubMed Web of Science ®Google Scholar
• FritzAPercyCJackAInternational Classification of Diseases for Oncology3rd edWHOGeneva200092-4-154534-8
   Google Scholar
• LaemmliUKCleavage of structural proteins during the assembly of the head of bacteriophage T4Nature197022752596806855432063
   PubMed Web of Science ®Google Scholar
• SchubertWTopological proteomics, toponomics, MELK-technologyAdv Biochem Eng Biotechnol20038318920912934931
   PubMedGoogle Scholar
• JohanssonASandströmPUllénAEpitope specificity of the monoclonal anticytokeratin antibody TS1Cancer Res199959148519892182
   PubMed Web of Science ®Google Scholar
• CheeverMAHiganoCSPROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineClin Cancer Res201117113520352621471425
   PubMed Web of Science ®Google Scholar
• DoehnCEsserNPauelsHGMode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinomaEur Urol20095612313318550267
   PubMed Web of Science ®Google Scholar
• MaslakPScheinbergDTargeted therapies for the myeloid leukaemiasExpert Opin Investig Drugs20009611971205
   PubMed Web of Science ®Google Scholar
• BaekSKimCSKimSBCombination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trialJ Transl Med2011917818822013914
   PubMed Web of Science ®Google Scholar
• WeinschenkTGouttefangeasCSchirleMIntegrated functional genomics approach for the design of patient-individual antitumor vaccinesCancer Res200262205818582712384544
   PubMed Web of Science ®Google Scholar
• KurotakiTTamuraYUedaGEfficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathwayJ Immunol200717931803181317641047
   PubMed Web of Science ®Google Scholar
• SomersanSLarssonMFonteneauJFBasuSSrivastavaPBhardwajNPrimary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cellsJ Immunol200116794844485211673488
   PubMed Web of Science ®Google Scholar
• VissersJLDe VriesIJSchreursMWThe renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytesCancer Res199959215554555910554034
   PubMed Web of Science ®Google Scholar
• ZismanAPantuckAJBuiMHLABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigenCancer Res200363164952495912941820
   PubMed Web of Science ®Google Scholar
• KimHLSunXSubjeckJRWangXYEvaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110Cancer Immunol Immunother20075671097110517146628
   PubMed Web of Science ®Google Scholar
• Al-AhmadieHAAldenDQinLXCarbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodiesAm J Surg Pathol200832337738218300814
   PubMed Web of Science ®Google Scholar
• ManféAZNorbertoLMarchesiniMLumachiFUsefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoidsIn Vivo20112561027102922021701
   PubMed Web of Science ®Google Scholar
• NeussHKoplinGRaueWReetzCMallJWAnalysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases – a prospective study in 231 patientsActa Chir Belg2011111421421821954736
   PubMed Web of Science ®Google Scholar
• RonkainenHSoiniYVaaralaMHKauppilaSHirvikoskiPEvaluation of neuroendocrine markers in renal cell carcinomaDiagn Pathol201052820462442
   PubMed Web of Science ®Google Scholar
• HolthöferHMiettinenAPaasivuoRCellular origin and differentiation of renal carcinomas. A fluorescence microscopic study with kidney-specific antibodies, antiintermediate filament antibodies, and lectinsLab Invest19834933173266193332
   PubMed Web of Science ®Google Scholar
• SunTPlutynskiAWardSRubinJBAn integrative view on sex differences in brain tumorsCell Mol Life Sci201572173323334225985759
   PubMed Web of Science ®Google Scholar
• HöglundMGisselssonDSollerMHansenGBElfvingPMitelmanFDissecting karyotyping patterns in renal cell carcinoma: an analysis of the accumulated cytogenetic dataCancer Genet Cytogenet20041531915325087
   PubMedGoogle Scholar
• MassariFCiccareseCPorcaroABQuantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinomaPathology201446652352625188333
   PubMed Web of Science ®Google Scholar
• SyringIMüllerSCEllingerJNovel tumor markers in the serum of testicular germ cell cancer patients: a reviewCurrent Biomarker Findings20144133137
   Google Scholar
• YangYLiJMaoSZhuHComparison of immunohistology using pan-CK and EMA in the diagnosis of lymph node metastasis of gastric cancer, particularly micrometastasis and isolated tumor cellsOncol Lett20135376877223426024
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration [homepage on the Internet]Silver Spring MD. Guidance for Industry. Potency Tests for Cellular and Gene Therapy Products Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM243392.pdfAccessed November 08, 2015
   Google Scholar